HC Wainwright Estimates Gossamer Bio FY2029 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Research analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Gossamer Bio in a research note issued on Thursday, January 30th. HC Wainwright analyst P. Trucchio anticipates that the company will earn $0.59 per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Gossamer Bio Trading Up 4.9 %

NASDAQ GOSS opened at $0.96 on Friday. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The firm has a 50 day simple moving average of $0.86 and a 200-day simple moving average of $0.90. Gossamer Bio has a one year low of $0.50 and a one year high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. The firm had revenue of $9.48 million for the quarter, compared to analysts’ expectations of $4.52 million.

Hedge Funds Weigh In On Gossamer Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GOSS. Marshall Wace LLP raised its stake in shares of Gossamer Bio by 170.8% in the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock valued at $3,002,000 after acquiring an additional 2,103,766 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Gossamer Bio by 204.7% during the 2nd quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company’s stock worth $1,844,000 after purchasing an additional 1,375,000 shares during the period. Jacobs Levy Equity Management Inc. raised its position in Gossamer Bio by 30.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock valued at $1,862,000 after purchasing an additional 442,895 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Gossamer Bio by 67.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company’s stock valued at $279,000 after buying an additional 124,913 shares during the period. Finally, Algert Global LLC purchased a new position in Gossamer Bio in the second quarter worth approximately $75,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.